Business Context and Reporting Period
This Form 6-K filing by CollPlant Holdings Ltd. (also referred to as CollPlant Biotechnologies Ltd.) covers the month of June 2018, with the report dated June 25, 2018. The filing addresses a significant corporate governance matter regarding the company's stock exchange listings.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal and corporate structural update rather than financial performance data.
Material Changes
- Delisting Approval: Shareholders and holders of Series I and Series K Warrants have approved an arrangement to voluntarily delist the Company's ordinary shares from the Tel Aviv Stock Exchange (TASE).
- Continued NASDAQ Listing: The Company intends to maintain its continued listing on NASDAQ following the TASE delisting.
- Court Submission: On June 24, 2018, the Company submitted a request to the District Court for approval of the Arrangement pursuant to Section 350 of the Israeli Companies Law of 1999.
Outlook, Risks, and Contingencies
The primary contingency involves the final approval of the Arrangement by the District Court. The filing notes that any person wishing to object to the Arrangement must submit an objection to the District Court within 10 days of June 25, 2018 (on or before July 5, 2018). The outcome of this court process is a material risk to the completion of the delisting plan.
Investor Verification Checklist
- Verify the final ruling of the District Court regarding the Arrangement after the July 5, 2018 objection deadline.
- Confirm the effective date of the delisting from the Tel Aviv Stock Exchange.
- Review the Company's subsequent filings to ensure the NASDAQ listing remains active and compliant.
- Check for any objections filed by shareholders or warrant holders that could delay or block the Arrangement.